Butterfly structure : a scaffold of therapeutic importance
Graphical abstract [Formula: see text].
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 12(2020), 3 vom: 17. Feb., Seite 179-182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choudhary, Shalki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Date Completed 02.11.2020 Date Revised 02.11.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2019-0313 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303844698 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303844698 | ||
| 003 | DE-627 | ||
| 005 | 20231225113706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2019-0313 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1012.xml |
| 035 | |a (DE-627)NLM303844698 | ||
| 035 | |a (NLM)31782310 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choudhary, Shalki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Butterfly structure |b a scaffold of therapeutic importance |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2020 | ||
| 500 | |a Date Revised 02.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Graphical abstract [Formula: see text] | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a COX2 | |
| 650 | 4 | |a butterfly | |
| 650 | 4 | |a chemistry | |
| 650 | 4 | |a di-aryl heterocycles | |
| 650 | 4 | |a toxicity | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Cyclooxygenase 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds |2 NLM | |
| 650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 700 | 1 | |a Silakari, Om |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 12(2020), 3 vom: 17. Feb., Seite 179-182 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:3 |g day:17 |g month:02 |g pages:179-182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2019-0313 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 3 |b 17 |c 02 |h 179-182 | ||